RxDoctor Payments Data

Kristin Boren, MD

Urology · Marietta, GANPI 1316108673

Payments from drug & device makers

$2,710in general payments, 2019–2025

Across 98 payments — averaging $27.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$485
  • Procept Biorobotics Corporation$305
  • Astellas Pharma US Inc$258
  • Teleflex LLC$204
  • 180 Medical, Inc.$190
  • SRS Medical Systems, Inc.$175
  • plus $1K from 19 others

What the payments were for

  • Food & beverage$2,63897%
  • Education$693%
  • Entertainment$30%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,710 in reported general payments places this provider in the 35th percentile of 369 urology providers in Georgia.

See all urology providers in Georgia

Medicare billing

Part B allowed, 2024
$125,654
Medicare patients
555
Services billed
1,583

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron196$125,914
GemtesaVibegron171$98,556
Estradiol105$7,055
Solifenacin Succinate159$7,031
Trospium Chloride ErTrospium Chloride42$6,350
Tamsulosin Hcl356$5,680
Testosterone17$3,101
Oxybutynin Chloride ErOxybutynin Chloride71$1,976
Finasteride150$1,817
Alfuzosin Hcl ErAlfuzosin Hcl77$1,296
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst67$1,224
Trospium Chloride20$1,108
Tolterodine Tartrate ErTolterodine Tartrate22$878
Fesoterodine Fumarate ErFesoterodine Fumarate18$875
Methenamine Hippurate18$747

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$258$125,914196 claims
Sumitomo Pharma America, Inc.Gemtesa$164$98,556171 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 369 urology providers in Georgia.

Other urology in Marietta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →